The initial results suggest that Exact’s test could be an alternative to others on the market, but the findings come from a ...

A leading provider of cancer screening and diagnostic tests, Exact Sciences relentlessly pursues smarter solutions providing the clarity to take life-changing action, earlier. Building on the succ ...

Exact Sciences (EXAS) stock rises as company announces release of data for blood-based cancer test on August 16. Read more ...

Exact’s test could compete with Guardant Health’s Shield blood test, which received approval from the Food and Drug Administration in July.

Exact Sciences Corporation ( NASDAQ: EXAS) Wells Fargo 2024 Healthcare Conference September 5, 2024 3:45 PM ET ...

Exact Sciences issued a news release earlier this ... blood tests have 30% fewer life years gained relative to Cologuard or ...

Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of the Cologuard ® and Oncotype ® tests, Exact ...

Exact Sciences Corp (EXAS) stock saw a modest uptick, ending the day at $64.12 which represents a slight increase of $5.74 or 9.83% from the prior close of $58.38. The stock opened at $58.46 and ...

Analyst Kyle Mikson CFA of Canaccord Genuity maintained a Buy rating on Exact Sciences (EXAS – Research Report), retaining the price ...

Per the DiMarino, it’s not an exact science ― if your current routine ... “Caffeine has a half-life of two to 10 hours, ...

Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of the Cologuard® and Oncotype® tests, Exact Sciences ...